M6P THERAPEUTICS
M6P Therapeutics develops biotechnology advances for lysosomal storage diseases. It provides research solutions on enzyme replacement and gene therapies. M6P Therapeutics was founded in 2017 and is based in Missouri, USA.
M6P THERAPEUTICS
Social Links:
Industry:
Biopharma Biotechnology Health Care Life Science Medical
Founded:
2017-01-01
Address:
St Louis, Missouri, United States
Country:
United States
Website Url:
http://www.m6ptherapeutics.com
Status:
Active
Similar Organizations
Bioxalis Medica
Bioxalis Medica Inc. develops drug delivery technologies for targeted liposomes for treating cancer.
Ceria Therapeutics
Ceria Therapeutics develops innovative and novel therapies to treat overactive and nonproductive inflammation to promote healing.
CHO Plus
CHO Plus develops biotechnology solutions to create therapeutic proteins for biopharmaceutical companies.
Enzyvant Sciences
Enzyvant Sciences is a biotechnology company which focuses on developing treatments for rare diseases.
Halo Therapeutics
Halo Therapeutics develops antivirals to prevent users from sickness.
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Mitotherapeutix
Mitotherapeutix develops siRNA-based drugs that focus on addressing difficult disease targets.
Embrace Scar Therapy
Embrace Scar Therapy develops tissue repair devices for plastic surgery to minimize scar formation.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Employees Featured
Official Site Inspections
http://www.m6ptherapeutics.com
- Host name: 183.248.222.35.bc.googleusercontent.com
- IP address: 35.222.248.183
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "M6P Therapeutics"
M6P – Therapeutics
Mannose 6-phosphate (M6P) is a specialized carbohydrate structure found on lysosomal enzymes. M6P enables newly synthesized lysosomal enzymes to bind to M6P receptors in …See details»
About Us – M6P - M6P – Therapeutics
M6P Therapeutics, or M6PT, is a life sciences company whose mission is clear and simple: to translate the M6PT innovation into more effective next generation therapies for individuals affected by lysosomal storage disorders (LSDs) – to …See details»
Leadership – M6P - M6P – Therapeutics
Our leadership team has collectively more than 100 years of experience and deep expertise in the discovery, non-clinical, clinical, and commercial development of drugs that treat rare diseases, …See details»
M6P Therapeutics - Crunchbase Company Profile & Funding
Founded Date 2017. Operating Status Active. Legal Name M6P Therapeutics, Inc. Company Type For Profit. M6P Therapeutics develops biotechnology advances for lysosomal storage …See details»
M6P Therapeutics - LinkedIn
M6P Therapeutics is developing the next-generation enzyme replacement and gene therapies for lysosomal storage disorders. We have discovered a novel method for significantly increasing...See details»
M6P THERAPEUTICS, INC. Company Profile - Dun & Bradstreet
Address: 11861 Westline Industrial Dr Saint Louis, MO, 63146-3305 United States. Phone: Website: www.m6ptherapeutics.com.See details»
M6P Therapeutics - VentureRadar
Website: https://m6ptherapeutics.com. M6P Therapeutics is a privately held, venture-backed platform company developing the next-generation enzyme replacement and gene therapies for …See details»
Our Focus – M6P - M6P – Therapeutics
Our mission is to translate the M6PT innovation into more effective next generation therapies for individuals affected by LSDs – to relieve suffering, to restore health, to increase hope, and to improve lives.See details»
M6P Therapeutics Receives Six Rare Pediatric Disease ... - Business …
Jan 28, 2021 · M6P Therapeutics is developing an innovative technology that regulates the natural mechanism for trafficking enzymes to lysosomes. The company’s bicistronic-S1S3 …See details»
M6P Therapeutics Presents Promising Preclinical Data …
Feb 11, 2022 · NAGLU-M6P is an enzyme replacement therapy approach utilizing co-expression of recombinant human NAGLU and S1S3, a modified GlcNAc-1-phosphotransferase, designed to increase M6P content and...See details»
Contact – M6P - M6P – Therapeutics
M6PT is focused on developing next generation enzyme replacement and gene therapies for LSDs. Lysosomal Storage Disorders . Enzymes Replacement Therapies .See details»
M6P Therapeutics Presents Promising Preclinical Data In
Feb 21, 2023 · M6P Therapeutics, a privately held life sciences company developing next-generation enzyme replacement and gene therapies for lysosomal storage disorders, …See details»
M6P Therapeutics Presents Novel AAV Gene Therapy Approach for …
Oct 11, 2022 · M6P Therapeutics is a privately held, venture-backed biotechnology company developing the next-generation of targeted enzyme replacement and gene therapies for …See details»
M6P Therapeutics Presents Promising Preclinical Data In
Feb 21, 2023 · M6P Therapeutics is a privately held, venture-backed biotechnology company developing the next-generation of targeted recombinant enzyme and gene therapies for …See details»
M6P Therapeutics Announces Formation of Distinguished, …
Feb 3, 2021 · LOUIS-- ( BUSINESS WIRE )-- M6P Therapeutics, a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal …See details»
M6P Therapeutics Presents Promising Preclinical Data In …
Feb 21, 2023 · M6P Therapeutics Presents Promising Preclinical Data In Lysosomal Storage Disorders At The 19th Annual WORLDSymposium™ 2023. Updated Tue, Feb 21, 2023, 5:00 …See details»
Our Science – M6P - M6P – Therapeutics
We Are Experts in Lysosomal Enzymes. Our team is the first to unlock the potential of mannose 6-phosphate (M6P) to improve and expand treatments for individuals with lysosomal storage …See details»
Working at M6P Therapeutics - Glassdoor
M6ptherapeutics.com; Saint Louis, MO; 1 to 50 Employees; Type: Company - Private; Revenue: Unknown / Non-ApplicableSee details»
M6P Therapeutics Announces Formation of Distinguished, …
Feb 3, 2021 · M6P Therapeutics (“M6PT” or “the Company”), a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal …See details»
M6P Therapeutics Presents Promising Preclinical Data in …
Feb 11, 2021 · M6P Therapeutics developed its novel bicistronic-S1S3 technology platform to maximize the natural mechanism for trafficking enzymes to lysosomes by enhancing …See details»